Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation

Strahlentherapie und Onkologie

Volumn 188, Issue 2, 2012, Pages 168-176

  Blattmann, C ^a   Oertel, S ^a   Thiemann, M ^a   Weber, K J ^a   Schmezer, P ^a   Zelezny, O ^a   Lopez Perez, R ^a   Kulozik, A E ^a   Debus, J ^a   Ehemann, V ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

H2AX expression; Atypical teratoid rhabdoid tumor; Histone deacetylase inhibitors; Osteosarcoma; Radiotherapy

Indexed keywords

HISTONE H2AX; VORINOSTAT; H2AFX PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; RADIOSENSITIZING AGENT;

ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IRRADIATION; OSTEOSARCOMA; PROTEIN EXPRESSION; RADIOSENSITIZATION; RHABDOID TUMOR; TUMOR CELL; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TERATOMA; TREATMENT OUTCOME; TUMOR CELL LINE;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; OSTEOSARCOMA; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TERATOMA; TREATMENT OUTCOME;

EID: 84858056311     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-011-0028-5     Document Type: Article

References (32)

1. Baschnagel A, Russo A, Burgan WE et al (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8:1589-1595
2. Biade S, Stobbe CC, Boyd JT et al (2001) Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 77:1033-1042
3. Blattmann C, Oertel S, Ehemann V et al (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237-245
4. Camphausen K, Burgan W, Cerra M et al (2004) Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316-321
5. Chen X, Wong J, Wong P et al (2011) Low dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 9:448-461
6. Chinnaiyan P, Vallabhaneni G, Armstrong E et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223-229
7. Chung YL, Lee MY, Pui NN (2009) Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30:1387-1397
8. Furchert SE, Lanvers-Kaminsky C, Jürgens H et al (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787-1794
9. Huang X, Darzynkiewicz Z (2006) Cytometric assessment of histone H2AX phosphorylation. Methods Mol Biol 314:73-80
10. Jeggo PA (1998) Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 150:80-91
11. Kaatsch P, Debling D, Blettner M et al (2009) Second malignant neoplasms after childhood cancer in Germany - results from the long-term follow- up of the German childhood cancer registry. Strahlenther Onkol 185:8-10
12. Kappler M, Taubert H, Bartel F et al (2005) Radiosensitization after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13:167-172
13. Karagiannis TC, Kn H, El-Osta A (2006) The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1:131-137
14. Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247-254
15. Klenke FM, Abdollahi A, Bischof M et al (2011) Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol 187:45-51
16. Lee M-J, Kim YS, Kummar S et al (2008) Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20:639-649
17. Levesque AA, Fanous AA, Poh A et al (2008) Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 7:252-262
18. MacPhail SH, Banath JP, Yu Y et al (2003) Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res 159:759-767
19. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216
20. Minucci S, Pelicci P (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
21. Munshi A, Tanaka T, Hobbs ML et al (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5:1967-1974
22. Niermann KJ, Moretti L, Giacalone NJ (2011) Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated aurora kinase B inhibition. Radiat Res 175:444-451
23. O'Connor OA, Heaney ML, Schwartz L et al (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173
24. Patties I, Jahns J, Hildebrandt G et al (2009) Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Strahlenther Onkol 185:331-338
25. Paull TT, Rogakou EP, Yamazaki V et al (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10:886-895
26. Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59:928-942
27. Purrucker JC, Fricke A, Ong MF et al (2010) HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. Oncol Rep 23:263-269
28. Rudat V, Bachmann N, Kuepper JH et al (2001) Overexpression of the DNA-binding domain of poly (ADP-ribose) polymerase inhibits rejoining of ionizing radiation-induced DNA-double-strand breaks. Int J Radiat Biol 77:303-307
29. Weiss C, Grabenbauer GG, Sauer R et al (2003) Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Strahlenther Onkol 179:93-98
30. Welte B, Suhr P, Bootke D et al (2010) Second malignancies in high-dose areas of previous tumor radiotherapy. Strahlenther Onkol 186:174-179
31. Wolff HA, Hennies S, Herrmann MK et al (2011) Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer. Strahlenther Onkol 187:52-58
32. Zhang Y, Jung M, Dritschilo A et al (2005) Enhancement of radiation sensitivity of human squamous cells by histone deacetylase inhibition. Radiat Res 163:488-493